ADM’s Probiotic Study: A Potential Game-Changer for Infant Colic Relief

Archer-Daniels-Midland Company ((ADM)) announced an update on their ongoing clinical study.

Archer-Daniels-Midland Company (ADM) is conducting a clinical study titled ‘A Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy of a Probiotic in Infantile Colic Symptoms Relief.’ The study aims to assess the effectiveness of a probiotic in alleviating symptoms of infantile colic in infants aged 3-12 weeks. This research is significant as it could offer a non-pharmaceutical solution to a common condition affecting infants and their families.

The intervention being tested is a dietary supplement in the form of a probiotic sachet, intended to provide relief from colic symptoms. The probiotic is administered daily over a four-week period, with each sachet containing 1.0E+9 Colony Forming Units (CFU).

The study employs a randomized, parallel intervention model with quadruple masking, meaning that participants, care providers, investigators, and outcomes assessors are all blinded to the treatment allocation. The primary purpose of this interventional study is treatment-focused.

Key dates for the study include its start date on June 21, 2022, and the latest update on April 8, 2025. The study is currently recruiting, indicating ongoing progress and commitment to obtaining conclusive results.

Market implications of this study could be significant for ADM, potentially enhancing its stock performance and investor sentiment if the probiotic proves effective. This could position ADM favorably against competitors in the dietary supplement market, particularly those targeting infant health.

The study is ongoing, and further details can be accessed on the ClinicalTrials portal.